BMY

As of July 27, 2026, Bristol-Myers Squibb Company has a market capitalization of $128.2 billion, making it a large-cap company in the Healthcare sector.

Of the 41 analyst ratings on Bristol-Myers Squibb Company, 46% are Buy or Strong Buy, 20 are Hold, and 2 are Sell. The overall consensus rating is Hold. Analyst ratings are opinions, not investment advice.

The average analyst price target for Bristol-Myers Squibb Company is $63.25. Individual targets range from $40.00 to $75.00.

Bristol-Myers Squibb Company is scheduled to report earnings on July 30, 2026. Analysts expect earnings of $1.60 per share.

Yes — Bristol-Myers Squibb Company has paid $2.51 per share in dividends over the trailing twelve months.

BMY has a beta of 0.23, meaning it has historically been less volatile than the broader market.

Bristol-Myers Squibb Company operates in the Healthcare sector, the Drug Manufacturers - General industry, and its stock trades on NYSE.